Analysts Offer Predictions for OptiNose FY2029 Earnings

OptiNose, Inc. (NASDAQ:OPTN) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of OptiNose in a note issued to investors on Friday, January 3rd. HC Wainwright analyst M. Caufield expects that the company will post earnings of $1.41 per share for the year. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.20) per share.

Separately, Piper Sandler lowered their target price on OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th.

OptiNose Price Performance

NASDAQ:OPTN opened at $6.50 on Monday. The business’s 50-day moving average is $7.81 and its two-hundred day moving average is $11.82. The firm has a market capitalization of $65.39 million, a PE ratio of -23.21 and a beta of -0.15. OptiNose has a 12 month low of $4.82 and a 12 month high of $31.50.

Institutional Investors Weigh In On OptiNose

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC grew its stake in shares of OptiNose by 442.3% during the second quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock valued at $14,425,000 after acquiring an additional 10,944,444 shares in the last quarter. Great Point Partners LLC boosted its holdings in OptiNose by 56.2% in the second quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock valued at $14,276,000 after purchasing an additional 4,940,779 shares during the last quarter. Stonepine Capital Management LLC grew its stake in OptiNose by 142.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock valued at $3,811,000 after purchasing an additional 3,338,580 shares in the last quarter. Rosalind Advisors Inc. increased its holdings in OptiNose by 9.8% during the 3rd quarter. Rosalind Advisors Inc. now owns 8,287,503 shares of the company’s stock worth $5,553,000 after purchasing an additional 740,355 shares during the last quarter. Finally, FMR LLC increased its holdings in OptiNose by 3.2% during the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company’s stock worth $11,083,000 after purchasing an additional 518,610 shares during the last quarter. Hedge funds and other institutional investors own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.